Your browser doesn't support javascript.
loading
Tanshinone IIA, a component of the self-made Xiao-Yin decoction, ameliorates psoriasis by inhibiting IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways.
Fu, Lei; Li, Meijiao; Wang, Peng; Chen, Lang; Huang, Jianqiu; Zhang, Hui.
Afiliación
  • Fu L; Department of Dermatology, Hainan Hospital of Traditional Chinese Medicine, Haikou, China.
  • Li M; Department of Dermatology, Hainan Hospital of Traditional Chinese Medicine, Haikou, China.
  • Wang P; Department of Dermatology, Hainan Hospital of Traditional Chinese Medicine, Haikou, China.
  • Chen L; Department of Dermatology, Hainan Hospital of Traditional Chinese Medicine, Haikou, China.
  • Huang J; Department of Dermatology, Hainan Hospital of Traditional Chinese Medicine, Haikou, China.
  • Zhang H; Department of Oncology, Hainan Hospital of Traditional Chinese Medicine, Haikou, China.
Skin Res Technol ; 30(2): e13577, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38284293
ABSTRACT

BACKGROUND:

Psoriasis is a persistent inflammatory dermatological disorder. Tanshinone IIA (tan-IIA) is a biologically active compound in the self-made Xiao-Yin decoction (SMXYD) and exhibits diverse biological properties, such as anti-proliferative and anti-inflammatory effects. The objective of this investigation was to assess the potential of tan-IIA as a therapeutic agent against psoriasis.

METHODS:

Network pharmacology was employed to ascertain the active constituents and potential pathways associated with SMXYD and psoriasis. We conducted CCK-8, qRT-PCR, and western blotting to assess the proliferation of HaCaT keratinocytes and the expression of IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways. Additionally, we used H&E staining, western blotting, and ELISA to evaluate the therapeutic effects and signaling pathways of tan-IIA in psoriasis-like mice induced by imiquimod (IMQ).

RESULTS:

Network pharmacology analysis identified eight hub compounds. The Th17/IL-17 signaling was found to be a potential therapeutic pathway of SMXYD against psoriasis, with JUN (AP-1) as the core molecule. Next, PTGS2 was selected as the target of tan-IIA against psoriasis using network pharmacology analysis. Molecular docking showed a high affinity between PTGS2 and tan-IIA. Tan-IIA treatment attenuated M-5-induced hyperproliferation and inflammation in HaCaT keratinocytes. Additionally, Tan-IIA downregulated the PTGS2/NF-κB/AP-1 pathway in HaCaT keratinocytes. In the IMQ-induced psoriasis-like mouse, tan-IIA significantly reduced the severity of skin lesions and downregulated the PTGS2/NF-κB/AP-1 pathway. Moreover, the combination of methotrexate (MTX) and tan-IIA further inhibited the IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways.

CONCLUSION:

The administration of tan-IIA has shown a positive effect on psoriasis by inhibiting the IL-17/IL-23 and PTGS2/NF-κB/AP-1 pathways. The findings suggest that it has promising qualities that make it a potential candidate for the development of future anti-psoriatic agents.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / FN-kappa B / Abietanos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Skin Res Technol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / FN-kappa B / Abietanos Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Skin Res Technol Asunto de la revista: DERMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China